Insmed’s (INSM) treatment of Duchenne muscular dystrophy, the single-stranded, non-replicating, recombinant adeno-associated virus serotype 9 ...

The first few months of 2025 brought hope to the rare disease community. Food and Drug Administration leadership promised ...

Avidity Biosciences surges 36% on reports that Novartis may eye a deal, with talks said to be early and interest from other suitors possible.

CPRX secures a key win as its Firdapse patent litigation settlement with Lupin shields U.S. sales from generic competition until 2035.

Investing.com -- Dyne Therapeutics Inc (NASDAQ:DYN) stock jumped 4.1% after Raymond James analyst Martin Auster upgraded the company from Outperform to Strong Buy and raised the price target to $35.00 ...

Paul Stephen Rudd began his acting career with commercials in 1991, before bagging a recurring role in the television drama ...

The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed on behalf of investors who acquired Capricor Therapeutics, Inc. ("Capricor" or the "Company") (NASDAQ: CAPR) ...

Certain proteins implicated in immune response and the body's process to stop bleeding may be biomarkers of BMD progression, ...